Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 14, 2014 - Issue 12
Submit an article Journal homepage
1,901
Views
27
CrossRef citations to date
0
Altmetric
Drug Evaluations

U300, a novel long-acting insulin formulation

Gemma SuttonInstitute for Research and Medicine Advancement (IRMEDICA), Barcelona, Spain
,
Joan MinguetInstitute for Research and Medicine Advancement (IRMEDICA), Barcelona, Spain;Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany+49 3379 3147890; +49 3379 3147892; [email protected]
,
Carmen FerreroDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Sevilla, Spain
&
Peter BramlageInstitute for Research and Medicine Advancement (IRMEDICA), Barcelona, Spain;Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Sevilla, Spain;Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany+49 3379 3147890; +49 3379 3147892; [email protected]
, MD PhD
Pages 1849-1860 | Published online: 14 Oct 2014

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Marc Rendell. (2019) Premix insulins in type 1 diabetes: the coming of degludec/aspart. Expert Opinion on Drug Metabolism & Toxicology 15:4, pages 341-348.
Read now
Marc Rendell. (2017) United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. Drug Design, Development and Therapy 11, pages 1209-1220.
Read now

Articles from other publishers (25)

Anil B. Jindal, Atharva R. Bhide, Sagar Salave, Dhwani Rana & Derajram Benival. (2023) Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Advanced Drug Delivery Reviews 198, pages 114862.
Crossref
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki & Christos Mantzoros. (2022) Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 137, pages 155332.
Crossref
Gagik R. Galstyan, Amir Tirosh, Hernando Vargas-Uricoechea, Maria Aileen Mabunay, Mathieu Coudert, Mubarak Naqvi, Valerie Pilorget & Niaz Khan. (2022) Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study. Diabetes Therapy 13:6, pages 1187-1202.
Crossref
Elnaz Zeynaloo, Logan D. Stone, Emre Dikici, Camillo Ricordi, Sapna K. Deo, Leonidas G. Bachas, Sylvia Daunert & Giacomo Lanzoni. (2022) Delivery of therapeutic agents and cells to pancreatic islets: Towards a new era in the treatment of diabetes. Molecular Aspects of Medicine 83, pages 101063.
Crossref
Jochen Seufert, Peter Wiesli, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Stefan Pscherer & Martin Pfohl. (2021) Switching the basal insulin to insulin glargine 300 U/ ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety . Diabetes, Obesity and Metabolism 24:1, pages 72-81.
Crossref
Janet B. McGill, Daniel Weiss, Marshall Grant, Marisa C. Jones, David M. Kendall & Byron J. Hoogwerf. (2020) Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. Journal of Diabetes 13:2, pages 164-172.
Crossref
Byron J. Hoogwerf, Kevin M. Pantalone, Marina Basina, Marisa C. Jones, Marshall Grant & David M. Kendall. (2021) Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 Diabetes. Endocrine Practice 27:1, pages 38-43.
Crossref
Guillermo E. Umpierrez, Elizabeth H. Holt, Daniel Einhorn & Janet B. McGill. (2020) Concentrated Insulins: Clinical Update of Therapeutic Options. Endocrine Practice 26, pages 1-11.
Crossref
Martin Pfohl, François R. Jornayvaz, Andreas Fritsche, Stefan Pscherer, Helmut Anderten, Katrin Pegelow & Jochen Seufert. (2020) Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes after failure of oral therapy in a real‐world setting. Diabetes, Obesity and Metabolism 22:5, pages 759-766.
Crossref
Sujoy Ghosh & Romik Ghosh. (2020) Glargine-300: An updated literature review on randomized controlled trials and real-world studies. World Journal of Diabetes 11:4, pages 100-114.
Crossref
D.R. Owens, T. S Bailey, C.G. Fanelli, J.-F. Yale & G.B. Bolli. (2019) Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation. Diabetes & Metabolism 45:4, pages 330-340.
Crossref
Gesine van Mark, Stefanie Lanzinger, Stefan Sziegoleit, Franz Josef Putz, Mesut Durmaz, Michaela Borscheller, Thomas Danne, Jochen Seufert, Reinhard W. Holl & Peter Bramlage. (2019) Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries. Advances in Therapy 36:7, pages 1628-1641.
Crossref
Alice Y. Y. Cheng, Dhiren K. Patel, Timothy S. Reid & Kathleen Wyne. (2019) Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Advances in Therapy 36:5, pages 1018-1030.
Crossref
Barbara Bohn, Peter Bramlage, Christian Wagner, Matthias Kaltheuner, Reinhard Welp, Stefan Sziegoleit, Artur Zimmermann, Hans Martin Reuter, Michael Hummel, Jörg Gloyer, Reinhard W. Holl & Thomas Danne. (2017) Welche Patienten aus der Routinebetreuung verwenden das neue Insulin-Analogon Glargin U300 im Vergleich zu Patienten mit Glargin U100?Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100. Wiener Medizinische Wochenschrift 168:15-16, pages 415-422.
Crossref
Thomas Forst. (2018) Möglichkeiten und Grenzen der aktuellen Insulintherapie. CME 15:1-2, pages 55-63.
Crossref
Hernando Vargas-Uricoechea. (2018) Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature. Journal of Diabetes Research 2018, pages 1-28.
Crossref
Thomas Forst. (2017) Möglichkeiten und Grenzen der aktuellen Insulintherapie. Info Diabetologie 11:6, pages 37-45.
Crossref
Hiroyuki IuchiMasaya SakamotoDaisuke MatsutaniHirofumi SuzukiRyuzo HoriuchiKazunori Utsunomiya. (2017) The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial. Diabetes Technology & Therapeutics 19:8, pages 457-462.
Crossref
Vincent C. Woo. (2017) A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus. Clinical Therapeutics 39:8, pages S12-S33.
Crossref
Ian Blumer & Maureen Clement. (2017) Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. Clinical Therapeutics 39:8, pages S1-S11.
Crossref
Martin Haluzík. (2017) Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm. Vnitřní lékařství 63:2, pages 87-92.
Crossref
Stephen Gough & Parth Narendran. 2017. Textbook of Diabetes. Textbook of Diabetes 399 413 .
Andreas Pfützner, Bernd Stratmann, Klaus Funke, Harald Pohlmeier, Ludger Rose, Jochen Sieber, Frank Flacke & Diethelm Tschoepe. (2016) Real-World Data Collection Regarding Titration Algorithms for Insulin Glargine in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology 10:5, pages 1122-1129.
Crossref
Thorsten Siegmund & Edin Zelihic. (2015) Optimierung der glykämischen Kontrolle und des kardiovaskulären Risikos. CardioVasc 15:3, pages 54-58.
Crossref
Andreas Liebl. (2015) Welches lang wirksame Insulin passt am besten?. MMW - Fortschritte der Medizin 157:7, pages 65-69.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.